A promising therapeutic target against T2D is represented by the Keap1–Nrf2 regulatory pathway, which has a central role in cellular protection against oxidative stress, thus diminishing ROS/RNS levels, which contribute to the deterioration of pancreatic β-cells and the consequent reduced release of insulin [173]. The gene discussed is INS; the disease is type 2 diabetes mellitus.